Abstract
The aim of the study was to look at the association of angiopoietin-2 (Ang-2) in Asian Indian subjects with different grades of glucose intolerance and in those with hypertension and metabolic syndrome (MS). Three groups were recruited from the Chennai Urban Rural Epidemiology Study, a population-based study in southern India, as follows: group 1, normal glucose tolerance(n = 45); group 2, impaired glucose tolerance (IGT) (n = 45); and group 3, type 2 diabetes mellitus (T2DM) (n = 40). Angiopoietin-2 was estimated by enzyme-linked immunosorbent assay. Hypertension was diagnosed based on medical history, drug treatment of hypertension, and/or if the subjects had systolic blood pressure at least 130 mm Hg and/or diastolic blood pressure at least 85 mm Hg. Metabolic syndrome was defined using modified National Cholesterol Education Program-Adult Treatment Panel III guidelines. Subjects with T2DM had higher age-adjusted Ang-2 values (3741 +/- 1429 pg/mL) compared with subjects with IGT (1907 +/- 855 pg/mL) and normal glucose tolerance (1462 +/- 856 pg/mL) (P for trend < .001). Regression analysis showed that there was a linear increase in mean Ang-2 values with increasing severity of glucose intolerance, even after adjusting for ag...Continue Reading
References
Jun 6, 1990·JAMA : the Journal of the American Medical Association·S M HaffnerJ K Patterson
Jul 1, 1997·Diabetes Care
Jul 4, 1997·Science·D Hanahan
Oct 16, 1999·The Journal of Biological Chemistry·N JonesD J Dumont
Feb 7, 2001·Diabetologia·S LehtoM Laakso
Feb 7, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·T KorffH G Augustin
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Oct 9, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Tamami OkamotoZenji Makita
Dec 31, 2002·Investigative Ophthalmology & Visual Science·Hitoshi TakagiYoshihito Honda
Jul 23, 2003·Current Pharmaceutical Design·F N KieferE J Battegay
Aug 14, 2003·The American Journal of Cardiology·Dirk C FelmedenGregory Y H Lip
Dec 25, 2003·Primary Care·Nancy J Rennert, Pamela Charney
Mar 12, 2004·Journal of the American College of Cardiology·Aun Yeong ChongGregory Y H Lip
Apr 28, 2004·Diabetes Care·Sarah WildHilary King
May 4, 2004·Annals of Medicine·Gregory Y H Lip, Andrew D Blann
Nov 25, 2004·Diabetes Care·Hoong Sern LimGregory Y H Lip
Mar 16, 2005·American Journal of Ophthalmology·Daisuke WatanabeHitoshi Takagi
Apr 13, 2005·Atherosclerosis·Hoong Sern LimAndrew D Blann
Sep 17, 2005·Journal of Internal Medicine·S K NadarG Y H Lip
Aug 3, 2007·The Journal of Biological Chemistry·Dachun YaoMichael Brownlee
Citations
Jul 24, 2012·Endocrine·Sazan RasulAlexandra Kautzky-Willer
Apr 17, 2012·Cardiovascular Research·Thomas KorffMarkus Hecker
Jun 28, 2011·Cardiovascular Diabetology·Sazan RasulAlexandra Kautzky-Willer
Jan 26, 2016·Metabolic Syndrome and Related Disorders·Harry Robberecht, Nina Hermans
Aug 1, 2013·European Journal of Heart Failure·Roberto LorbeerWolfgang Lieb
May 30, 2016·Angiogenesis·Mohamed Abo El-AsrarAlShaimaa Abo Bakr
Oct 4, 2014·PloS One·Yi-Chun TsaiHung-Chun Chen
Oct 21, 2016·Journal of Endocrinological Investigation·A M IsidoriD Fiore
Sep 8, 2016·Obesity·Roberto LorbeerWolfgang Lieb
Oct 26, 2016·Current Diabetes Reports·Peter A Campochiaro, Kevin G Peters
Dec 20, 2016·Scientific Reports·Yi-Chun TsaiHung-Chun Chen
May 1, 2018·Postgraduate Medicine·Khalid SiddiquiKhalid Al-Rubeaan
Feb 16, 2018·International Journal of Vascular Medicine·Kwame YeboahBen Gyan
Nov 1, 2015·Circulation·Hertzel C GersteinUNKNOWN Outcome Reduction With Initial Glargine Intervention Trial Investigators
Apr 18, 2019·Journal of Pediatric Hematology/oncology·Nevine G AndrawesAmna M Ibrahim
Nov 19, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Chang ChuBerthold Hocher